First Financial Bank Trust Division Has $6.89 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

First Financial Bank Trust Division lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 74,597 shares of the biopharmaceutical company’s stock after selling 2,575 shares during the period. First Financial Bank Trust Division’s holdings in Gilead Sciences were worth $6,891,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in Gilead Sciences during the third quarter worth approximately $25,000. Valued Wealth Advisors LLC grew its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $33,000. Cedar Wealth Management LLC lifted its position in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 160 shares during the period. Finally, Friedenthal Financial bought a new position in Gilead Sciences during the third quarter worth $50,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded down $0.54 during midday trading on Thursday, reaching $91.83. The company had a trading volume of 2,384,002 shares, compared to its average volume of 7,043,598. The stock has a market cap of $114.44 billion, a P/E ratio of 1,020.33, a P/E/G ratio of 2.38 and a beta of 0.18. The company’s 50 day moving average price is $91.70 and its 200 day moving average price is $82.15. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the previous year, the firm posted $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 8,500 shares of Gilead Sciences stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $91.96, for a total value of $781,660.00. Following the completion of the transaction, the chief financial officer now owns 132,373 shares in the company, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock valued at $41,902,086 over the last ninety days. 0.29% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research reports. Barclays upped their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Piper Sandler upped their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Citigroup started coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. Twelve analysts have rated the stock with a hold rating, twelve have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.